Search

Displaying results 3491 - 3500 of 4231 in total
  1. Drug

    ADP-A2M4CD8

    go.drugbank.com/drugs/DB25733
    Investigational

    ADP-A2M4CD8 is under investigation in clinical trial NCT04044859 (ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS

  2. Drug

    Difloxacin

    go.drugbank.com/drugs/DB11511
    ExperimentalVet approved

    As an antibacterial, it presents a broad bactericidal spectrum and its effects are dependent on its concentration.

  3. Drug

    Tiletamine

    go.drugbank.com/drugs/DB11549
    ExperimentalVet approved

    Tiletamine hydrochloride, the salt form, exists as odorless white crystals.

  4. Drug

    PZM21

    go.drugbank.com/drugs/DB14030
    Experimental

    novel μ-opioid receptor (MOPr) ligand that has been reported to induce minimal arrestin recruitment and be devoid of the respiratory depressant effects characteristic of classical μ-opioid ligands such as

  5. Drug

    AM336

    go.drugbank.com/drugs/DB06563
    Experimental

    It was investigated as a potential treatment for various pain conditions.

  6. Drug

    ZYC300

    go.drugbank.com/drugs/DB04986
    Investigational

    It is designed as a vaccine, intended to increase immune system sensitivity to CYP1B1, an enzyme highly prevalent in tumor cells.

  7. Drug

    Tanespimycin

    go.drugbank.com/drugs/DB05134
    Investigational

    Tanespimycin, manufactured by Conforma Therapeutics is under development as a small molecule inhibitor of heat shock protein 90 (HSP90).

  8. Drug

    ABBV-514

    go.drugbank.com/drugs/DB17586
    Investigational

    ABBV-514 is in development for the treatment of non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) as a single agent and in combination with a PD-1 inhibitor.[L45464]

  9. Drug

    D-threo-neopterin

    go.drugbank.com/drugs/DB02385
    Experimental

    (From Stedman, 26th ed) Neopterin also serves as a precursor in the biosynthesis of biopterin.

  10. Drug

    Brentuximab

    go.drugbank.com/drugs/DB05471
    Investigational

    SGN-30 has demonstrated objective antitumor responses as a single agent in phase II clinical trials. … It is available commercially as the monoclonal antibody portion of the antibody-drug conjugate [brentuximab vedotin].